Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton May 13, 2024 2:37pm
213 Views
Post# 36037311

RE:TAR-200

RE:TAR-200It's an unusual treatment. They insert a silicone tube into the bladder which slowly releases the drug gemcitabine over a period of a few days to a week. After 21 days they remove the device and immediately put in a new one. They do this 8 times - once every 3 weeks in the first 24 weeks. Then .6 more times - once every 12 weeks up to 96 weeks. So it's a non-stop treatment by way of slow gemcitabine release for 2 years.

They only have results for 2 years so it's anybody's guess what happens after 2 years when the treatments stop.

Camphikefish wrote: There's a news release from JnJ on May 4th stating their TAR-200 drug shows an 80% CR in BCG nonresponsive patients. I've not followed things closely here for a while. Has anyone else taken a look at this? I'm curious about what everyone thinks about their drug and the study. 


<< Previous
Bullboard Posts
Next >>